Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Clinical characteristics of anti-Jo-1-positive interstitial lung disease Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019
Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013
Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020
The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia Source: International Congress 2016 – Connective tissue disorders Year: 2016
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015
Clinical features of interstitial lung disease in polymyositis and dermatomyositis Source: Eur Respir J 2006; 28: Suppl. 50, 828s Year: 2006
Pulmonary function in progressive systemic sclerosis Source: Eur Respir J 2002; 20: Suppl. 38, 62s Year: 2002
Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
Significance of histopathologic features suggesting connective tissue disease in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015
Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018
Clinical and laboratory features of systemic sclerosis with pulmonary involvement Source: Eur Respir J 2001; 18: Suppl. 33, 512s Year: 2001
Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia Source: International Congress 2017 – Lung function testing Year: 2017
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003
Clinical features of microscopic polyangiitis with usual interstitial pneumonia-like fibrosis in comparison with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014
Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease Source: Eur Respir J, 53 (5) 1802182; 10.1183/13993003.02182-2018 Year: 2019